Concepedia

Jeri Kim

JK

Statistics

Publications

79

Citations

6.3K

H-Index

38

Active since

1999

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

Erasmus MC

University of Washington

Institute of Cancer Research

Jeri Kim is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, urology, and oncology.

ORCID

Top concepts

Publications per year

1999–2024

79

Publications

79

Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study

Emmanuel S. Antonarakis, Josep M. Piulats, Marine Gross‐Goupil et al. · Journal of Clinical Oncology · 2019 · 679 citations · Full text

Platinum-Based Chemotherapy for Variant Castrate-Resistant Prostate Cancer

Ana M. Aparicio, Andrea Harzstark, Paul G. Corn et al. · Clinical Cancer Research · 2013 · 456 citations · Full text

Phase I Trial of the Proteasome Inhibitor Bortezomib in Patients With Advanced Solid Tumors With Observations in Androgen-Independent Prostate Cancer

Christos N. Papandreou, Danai Daliani, Darrell Nix et al. · Journal of Clinical Oncology · 2004 · 436 citations · Full text

Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

Shi‐Ming Tu, Randall E. Millikan, Bayabel Mengistu et al. · The Lancet · 2001 · 395 citations

, , +8

Fingerprinting the circulating repertoire of antibodies from cancer patients

Paul J. Mintz, Jeri Kim, Kim‐Anh Do et al. · Nature Biotechnology · 2002 · 332 citations

, , +8

1–5 of 79